Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody

J Dermatol. 2007 Jul;34(7):473-6. doi: 10.1111/j.1346-8138.2007.00313.x.

Abstract

Two women (aged 46 and 56 years) developed annular erythema on their sun-exposed skin, including their forearms and faces, after biweekly i.v. administration of paclitaxel for 3-4 months to treat breast cancer. Both cases showed interface changes of basal keratinocytes and high titers of serum anti-SSA/Ro antibody. The diagnoses of paclitaxel-induced cutaneous lupus erythematosus (LE) were made because the skin eruptions cleared rapidly within 3 weeks after the paclitaxel treatment was discontinued. Paclitaxel is proposed to be a causative agent that can provoke cutaneous LE.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Antinuclear / blood*
  • Antineoplastic Agents, Phytogenic / adverse effects*
  • Arm / pathology
  • Breast Neoplasms / drug therapy
  • Female
  • Humans
  • Lupus Erythematosus, Cutaneous / chemically induced*
  • Lupus Erythematosus, Cutaneous / immunology
  • Lupus Erythematosus, Cutaneous / pathology
  • Middle Aged
  • Paclitaxel / adverse effects*
  • Sjogren's Syndrome / drug therapy
  • Sjogren's Syndrome / immunology
  • Skin / pathology

Substances

  • Antibodies, Antinuclear
  • Antineoplastic Agents, Phytogenic
  • SS-A antibodies
  • Paclitaxel